That's an improvement on last quarter. Improved sales (+3%), recovery rate (+4%), grade (+0.06%) and margin (+22%)
Cash margin per dmt this quarter of US$534 vs US$439 for the previous quarter and in the ballpark of the US$542 that was achieved in the December quarter.
Cash profit of US$24.4m for the quarter.
Cash balance increased by US$24m to US$84.8m (AUD$114.1m)
- Forums
- ASX - By Stock
- GXY
- Ann: Quarterly Report - June 2018
Ann: Quarterly Report - June 2018, page-5
-
- There are more pages in this discussion • 181 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GXY (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online